Funnel Bio Signs $2B AI Antibody Deal

Beijing-based Funnel Bio will use its AI antibody platform on targets nominated by Third Rock Ventures under a partnership valued at over $2 billion.

Updated on Nov. 10, 2026 in Biotech

Funnel Bio Signs $2B AI Antibody Deal

Funnel Bio, a Beijing-based company co-founded in February 2026, signed a partnership valued at $2 billion-plus with Third Rock Ventures to apply its epitope-guided AI antibody discovery platform. The collaboration includes an undisclosed platform access fee and total potential fees of up to $2.16 billion.

Why it matters

The deal pairs generative AI and physics-based design with a major venture investor, offering an alternative to conventional antibody discovery that relies on animal immunisation and phage display screening. It signals growing investment in AI-driven biologics design from China-based companies.

The partnership carries total potential fees of up to $2.16 billion and a first development candidate from a related Perpetual Medicine program is slated for delivery 18 months after the agreement. The undisclosed platform access fee and the clinical prospects of any resulting candidates remain unknown.

The players

Funnel Bio

Funnel Bio is a Beijing-based AI antibody discovery company, also known as Fangnuo Biotech, that combines generative algorithms with physics-based energy functions to design biologics.

Third Rock Ventures

Third Rock Ventures is a US-based venture capital firm known for backing early-stage life sciences companies.

Perpetual Medicine

Perpetual Medicine is a Shanghai-based company developing peptide-based therapeutics through a partnership with Third Rock Ventures.

The details

Funnel Bio will nominate targets to its platform through the Third Rock Ventures collaboration, and the company will generate antibodies by linking molecular design with the intended mechanism of action. The company, known in China as Fangnuo Biotech, was co-founded by Dr Liu Jintan and Dr Mingchen Chen.

Timeline

  1. February 2026: Funnel Bio is co-founded by Dr Liu Jintan and Dr Mingchen Chen.

  2. June 2026: The first development candidate from the Perpetual Medicine alliance is due for delivery.

The Tech Race

The partnership positions AI-driven, epitope-guided design as an alternative to the animal immunisation and phage display workflow that has long dominated antibody discovery. It adds to a competitive push by Chinese biotech firms to apply generative models to biologics design.

The partnership is aimed at producing drug candidates rather than consumer products, so its effects on patients will depend on whether candidates reach clinical testing. Readers should not expect near-term changes to available treatments from this agreement alone.

The takeaway

AI-designed antibodies are moving from research concept toward large commercial partnerships, but the timeline from platform deal to approved therapy remains long. Watch for first candidate deliveries and any clinical trial announcements to judge whether the approach delivers.

Further reading

For broader context on how AI is reshaping drug development, explore our Biotech coverage.

Source note: This article includes information reported by Pharmaphorum.